Status:
COMPLETED
Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Nonalcoholic Fatty Liver Disease
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The investigators' aim is to determine whether probiotic and prebiotic treatment plus lifestyle advice is more effective in reducing hepatic fat content than lifestyle advice alone in patients with No...
Eligibility Criteria
Inclusion
- Age 18 to 70 years
- Fatty liver identified by imaging studies including ultrasound, computer tomography or magnetic resonance imaging
- Elevated alanine aminotransferase (ALT) according to Prati's criteria (\>30 IU/l in men and \>19 IU/l in women)18
- Written informed consent obtained
Exclusion
- Positive hepatitis B surface antigen, anti-hepatitis C virus antibody, or anti-nuclear antibody titer above 1/160
- Alcohol consumption above 30 g per week in men or 20 g per week in women
- ALT above 10 times the upper limit of normal
- Liver decompensation, as evidenced by bilirubin above 50 µmol/l, platelet count below 100 × 109/l, prothrombin time above 1.3 times the upper limit of normal, albumin below 35 g/l, presence of ascites or varices
- Use of systemic corticosteroids and methotrexate in the last 6 months
- Evidence of hepatocellular carcinoma
- Terminal illness or cancer, unless in complete remission for more than 5 years
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00870012
Start Date
February 1 2009
End Date
January 1 2012
Last Update
February 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong SAR, China